Currently out of the existing stock ratings of Daniel Stauder, 18 are a BUY (100%).

Daniel Stauder

Work Performance Price Targets & Ratings Chart

Analyst Daniel Stauder, currently employed at JMP, carries an average stock price target met ratio of 50% that have a potential upside of 11.16% achieved within 91 days.

Daniel Stauder’s has documented 35 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AORT, Artivion at 08-May-2026.

Wall Street Analyst Daniel Stauder

Analyst best performing recommendations are on AORT (ARTIVION).
The best stock recommendation documented was for AORT (ARTIVION) at 8/8/2025. The price target of $42 was fulfilled within 3 days with a profit of $1.05 (2.56%) receiving and performance score of 8.55.

Average potential price target upside

AORT Artivion ATRC AtriCure LMAT LeMaitre Vascular

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 17-Jun-2025

$36

$12.39 (52.48%)

$48

1 months 3 days ago
(16-Jun-2026)

1/4 (25%)

$14.55 (67.83%)

52

Buy Since 18-Feb-2022

$44

$20.39 (86.36%)

$58

2 months 11 days ago
(08-May-2026)

18/23 (78.26%)

$18.59 (73.16%)

317

Buy Since 23-Oct-2024

$48

$24.39 (103.30%)

$47

2 months 11 days ago
(08-May-2026)

5/6 (83.33%)

$22.59 (88.90%)

131

Buy Since 08-Aug-2022

$55

$31.39 (132.95%)

$32

8 months 12 days ago
(07-Nov-2025)

5/6 (83.33%)

$10.13 (22.58%)

657

Buy Since 02-Mar-2022

$46

$22.39 (94.83%)

$36

9 months 20 days ago
(29-Sep-2025)

10/10 (100%)

$3.96 (9.42%)

184

Show more analysts

Please expand the browser size to see the chart

Which stock is Daniel Stauder is most bullish on?

Potential upside of $25.37 has been obtained for LMAT (LEMAITRE VASCULAR)

Which stock is Daniel Stauder is most reserved on?

Potential downside of $17.05 has been obtained for ATRC (ATRICURE)

What Year was the first public recommendation made by Daniel Stauder?

On 2023

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?